Neuropace (NPCE) Stock Forecast: StockMap's 2-Week Call
NPCE stock forecast: StockMap's model leans Underperform on Neuropace for the two weeks after the Nov 19 close, toward NPCE trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 5 two-week windows on NPCE since Aug 21; by chance, a call on the same dates was right 58% of the time.
Neuropace last closed at $8.14, -0.97% on the session.
Against the IVW growth benchmark the position is +1.36% over the forecast window.
Neuropace's market cap is $280.45M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).
Where NPCE sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
29 daily calls for NPCE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Neuropace in the 9th percentile on return on equity, where 100 is best.
Neuropace is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks Neuropace as the 84th largest of the 141 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 69 Neutral, 55 Moderate Underperform, 14 Strong Underperform and 3 Moderate Outperform.
On that composite Neuropace ranks 91st of 141 in the group, against a group median of -0.18.